JP2021512896A5 - - Google Patents

Info

Publication number
JP2021512896A5
JP2021512896A5 JP2020542569A JP2020542569A JP2021512896A5 JP 2021512896 A5 JP2021512896 A5 JP 2021512896A5 JP 2020542569 A JP2020542569 A JP 2020542569A JP 2020542569 A JP2020542569 A JP 2020542569A JP 2021512896 A5 JP2021512896 A5 JP 2021512896A5
Authority
JP
Japan
Prior art keywords
formulation
migalastat
use according
salt
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020542569A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512896A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/016853 external-priority patent/WO2019157056A1/en
Publication of JP2021512896A publication Critical patent/JP2021512896A/ja
Publication of JP2021512896A5 publication Critical patent/JP2021512896A5/ja
Priority to JP2023192942A priority Critical patent/JP2024026080A/ja
Withdrawn legal-status Critical Current

Links

JP2020542569A 2018-02-06 2019-02-06 古典型ファブリー病患者の治療 Withdrawn JP2021512896A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023192942A JP2024026080A (ja) 2018-02-06 2023-11-13 古典型ファブリー病患者の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862626992P 2018-02-06 2018-02-06
US62/626,992 2018-02-06
PCT/US2019/016853 WO2019157056A1 (en) 2018-02-06 2019-02-06 Treatment of patients with classic fabry disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023192942A Division JP2024026080A (ja) 2018-02-06 2023-11-13 古典型ファブリー病患者の治療

Publications (2)

Publication Number Publication Date
JP2021512896A JP2021512896A (ja) 2021-05-20
JP2021512896A5 true JP2021512896A5 (enExample) 2023-06-06

Family

ID=65494622

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020542569A Withdrawn JP2021512896A (ja) 2018-02-06 2019-02-06 古典型ファブリー病患者の治療
JP2023192942A Pending JP2024026080A (ja) 2018-02-06 2023-11-13 古典型ファブリー病患者の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023192942A Pending JP2024026080A (ja) 2018-02-06 2023-11-13 古典型ファブリー病患者の治療

Country Status (20)

Country Link
US (1) US20210038579A1 (enExample)
EP (2) EP4316589A3 (enExample)
JP (2) JP2021512896A (enExample)
KR (1) KR20200128675A (enExample)
CN (1) CN112203657A (enExample)
AR (1) AR114392A1 (enExample)
AU (2) AU2019217603A1 (enExample)
DK (1) DK3749308T3 (enExample)
ES (1) ES2969263T3 (enExample)
FI (1) FI3749308T3 (enExample)
HR (1) HRP20240025T1 (enExample)
HU (1) HUE064761T2 (enExample)
LT (1) LT3749308T (enExample)
PL (1) PL3749308T3 (enExample)
PT (1) PT3749308T (enExample)
RS (1) RS65103B1 (enExample)
SI (1) SI3749308T1 (enExample)
SM (1) SMT202400027T1 (enExample)
TW (1) TWI869336B (enExample)
WO (1) WO2019157056A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX351004B (es) 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
AU2018277756A1 (en) 2017-05-30 2020-01-23 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
EP4717319A3 (en) 2018-02-06 2026-06-10 Amicus Therapeutics, Inc. Methods of treating fabry disease in pregnant patients
LT3840753T (lt) 2018-08-20 2024-11-11 Amicus Therapeutics, Inc. Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
JP2024525760A (ja) * 2021-07-12 2024-07-12 アミカス セラピューティックス インコーポレイテッド 小児患者のファブリー病を治療する方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
MX351004B (es) * 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
EP3432882B1 (en) * 2016-03-22 2021-09-01 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having the g9331a mutation in the gla gene
WO2018017721A1 (en) * 2016-07-19 2018-01-25 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients
EA202090242A1 (ru) * 2017-07-19 2020-05-26 Амикус Терапьютикс, Инк. Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов

Similar Documents

Publication Publication Date Title
JP7737367B2 (ja) α1A-AR部分アゴニストを用いて神経障害を治療するための方法
JP2020033360A5 (enExample)
JP2020531550A5 (enExample)
IL272893B2 (en) Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
CA2966195C (en) Oral adamantine in the treatment of gait disorders in multiple sclerosis patients
EP2129400A2 (en) Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
JP6511492B2 (ja) 女性胃不全麻痺に関係する症状の処置
JP2015517994A (ja) ハロフジノンの剤形およびその使用
Prommer The role of fentanyl in cancer-related pain
JP2020510675A (ja) ミトコンドリア起源のrosの産生の特異的阻害剤を使用した、薬物誘発qt間隔延長に関連するリスクの予防
EA005524B1 (ru) Применение дексмедетомидина для седативного воздействия в отделении интенсивной терапии
US20080311196A1 (en) All Day Rhinitic Condition Treatment Regimen
JP2013536206A5 (enExample)
DINAI et al. Bradycardia induced by interaction between quinidine and ophthalmic timolol
Chervinsky et al. Long-term cardiovascular safety of salmeterol powder pharmacotherapy in adolescent and adult patients with chronic persistent asthma: a randomized clinical trial
ES2977185T3 (es) Administración intranasal de ketamina a pacientes con cefalea en racimos
JPS5823618A (ja) 精神分裂症を治療する組成物
EP2727595B1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
Adams et al. Evaluation and pharmacologic approach to patients with resistant hypertension
US12303503B1 (en) Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain
US7608625B2 (en) Method for treating bruxism and bruxism-related diseases
EP3711759B1 (en) Blend containing aripiprazole and a carbamate compound for prevention, mitigation, or treatment of schizophrenia
Maesen et al. Formoterol suspension aerosol: comparison with formoterol solution aerosol for 12 weeks in asthmatic patients
WO2017100324A1 (en) Combination therapy for treating female hypoactive sexual desire disorders
Ishikawa et al. Elimination of unstable angina by diltiazem under temporary pacing